Some people fail to see the obvious .." The objective of the...

Some people fail to see the obvious ..
" The objective of the meeting was to seek guidance on the plans for further development of BNC210 in a second Phase 2 trial in PTSD patients using the newly developed tablet formulation and aiming for the exposure levels predicted from the pharmacometric analyses to have potential for clinical benefit."

There is a different tablet formulation-larger dose and slow release-animal models already were demonstrating the benefit of BNC210.
The potential for SP rise is very clear. The CR will happen but the circumstances will be improved.